131I-rose bengal therapy in hepatoblastoma patients

J. de Kraker; C. A. Hoefnagel; P. A. Voûte

doi:10.1016/0277-5379(91)90229-7

131I-rose bengal therapy in hepatoblastoma patients

J. de Kraker
, C. A. Hoefnagel
, P. A. Voûte

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

If conventional treatment modalities have failed in hepatoblastoma patients and no distant metastases can be demonstrated therapy with radionuclide agents can be considered. In 6 patients diagnostic technetium-99m (99mTc)-disofenin and two iodine-131 (131I)-rose bengal scans were made. 2 patients demonstrated specific uptake of disofenin. One of these had a positive scintigram with radiolabelled rose bengal. This patient was subsequently treated with 1.1 GBq 131I-rose bengal. No toxicity was observed. A clear decrease in the level of alpha-fetoprotein indicated a response and demonstrated that this radiopharmaceutical can be used for tumour targeted radiation therapy in selected patients with therapy resistant tumours

Original language	English
Pages (from-to)	613-615
Journal	European journal of cancer (Oxford, England
Volume	27
Issue number	5
DOIs	https://doi.org/10.1016/0277-5379(91)90229-7
Publication status	Published - 1991

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/0277-5379(91)90229-7

Cite this

@article{1f3fd5e0e010443ca3ca414df83ab8c0,

title = "131I-rose bengal therapy in hepatoblastoma patients",

abstract = "If conventional treatment modalities have failed in hepatoblastoma patients and no distant metastases can be demonstrated therapy with radionuclide agents can be considered. In 6 patients diagnostic technetium-99m (99mTc)-disofenin and two iodine-131 (131I)-rose bengal scans were made. 2 patients demonstrated specific uptake of disofenin. One of these had a positive scintigram with radiolabelled rose bengal. This patient was subsequently treated with 1.1 GBq 131I-rose bengal. No toxicity was observed. A clear decrease in the level of alpha-fetoprotein indicated a response and demonstrated that this radiopharmaceutical can be used for tumour targeted radiation therapy in selected patients with therapy resistant tumours",

author = "\{de Kraker\}, J. and Hoefnagel, \{C. A.\} and Vo{\^u}te, \{P. A.\}",

year = "1991",

doi = "10.1016/0277-5379(91)90229-7",

language = "English",

volume = "27",

pages = "613--615",

journal = "European journal of cancer (Oxford, England",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - 131I-rose bengal therapy in hepatoblastoma patients

AU - de Kraker, J.

AU - Hoefnagel, C. A.

AU - Voûte, P. A.

PY - 1991

Y1 - 1991

N2 - If conventional treatment modalities have failed in hepatoblastoma patients and no distant metastases can be demonstrated therapy with radionuclide agents can be considered. In 6 patients diagnostic technetium-99m (99mTc)-disofenin and two iodine-131 (131I)-rose bengal scans were made. 2 patients demonstrated specific uptake of disofenin. One of these had a positive scintigram with radiolabelled rose bengal. This patient was subsequently treated with 1.1 GBq 131I-rose bengal. No toxicity was observed. A clear decrease in the level of alpha-fetoprotein indicated a response and demonstrated that this radiopharmaceutical can be used for tumour targeted radiation therapy in selected patients with therapy resistant tumours

AB - If conventional treatment modalities have failed in hepatoblastoma patients and no distant metastases can be demonstrated therapy with radionuclide agents can be considered. In 6 patients diagnostic technetium-99m (99mTc)-disofenin and two iodine-131 (131I)-rose bengal scans were made. 2 patients demonstrated specific uptake of disofenin. One of these had a positive scintigram with radiolabelled rose bengal. This patient was subsequently treated with 1.1 GBq 131I-rose bengal. No toxicity was observed. A clear decrease in the level of alpha-fetoprotein indicated a response and demonstrated that this radiopharmaceutical can be used for tumour targeted radiation therapy in selected patients with therapy resistant tumours

U2 - 10.1016/0277-5379(91)90229-7

DO - 10.1016/0277-5379(91)90229-7

M3 - Article

C2 - 1647184

SN - 0959-8049

VL - 27

SP - 613

EP - 615

JO - European journal of cancer (Oxford, England

JF - European journal of cancer (Oxford, England

IS - 5

ER -

131I-rose bengal therapy in hepatoblastoma patients

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this